1208459-96-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(BOC)-6-fluoro-indole is used as a building block for the synthesis of pharmaceutical compounds, specifically in the production of potential anticancer and antiviral agents. Its unique structure and reactivity contribute to the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Organic Chemistry Research:
N-(BOC)-6-fluoro-indole is utilized as a versatile compound in organic chemistry research, enabling the exploration of new chemical reactions and the synthesis of complex organic molecules. Its unique properties facilitate the discovery of innovative synthetic pathways and the development of novel chemical methodologies.
Used in Medicinal Chemistry Research:
N-(BOC)-6-fluoro-indole serves as a key component in medicinal chemistry research, where it is employed to design and optimize drug candidates with enhanced pharmacological properties. Its strategic importance in drug discovery allows for the development of new therapeutic agents with improved safety, efficacy, and selectivity.
Used in Materials Science Research:
N-(BOC)-6-fluoro-indole is also studied for its potential use in the development of novel materials and chemical reactions. Its unique structure and reactivity make it a promising candidate for the creation of advanced materials with specific properties and applications in various industries.

Upstream product

• 399-51-9 6-fluoro-1H-indole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1627721-59-8 tert-butyl 6-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate 
• 1314406-46-6 3-bromo-6-fluoro-indole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase

Tryptophan 2,3-dioxygenase (TDO2) is a heme-containing enzyme constitutively expressed at high concentrations in the liver and responsible for l-tryptophan (l-Trp) homeostasis. Expression of TDO2 in cancer cells results in the inhibition of immune-mediated tumor rejection due to an enhancement of l-Trp catabolism via the kynurenine pathway. In the study herein, we disclose a new 6-(1H-indol-3-yl)-benzotriazole scaffold of TDO2 inhibitors developed through rational design, starting from existing inhibitors. Rigidification of the initial scaffold led to the synthesis of stable compounds displaying a nanomolar cellular potency and a better understanding of the structural modulations that can be accommodated inside the active site of hTDO2.

INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.

NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also 10 relates to a process for manufacturing compounds of Formula I.

Bismuth Acetate as a Catalyst for the Sequential Protodeboronation of Di- and Triborylated Indoles

Bismuth(III) acetate is a safe, inexpensive, and selective facilitator of sequential protodeboronations, which when used in conjunction with Ir-catalyzed borylations allows access to a diversity of borylated indoles. The versatility of combining Ir-catalyzed borylations with Bi(III)-catalyzed protodeboronation is demonstrated by selectively converting 6-fluoroindole into products with Bpin groups at the 4-, 5-, 7-, 2,7-, 4,7-, 3,5-, and 2,4,7-positions and the late-stage functionalization of sumatriptan.